Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Spero Therapeutics stock

Own Spero Therapeutics stock in just a few minutes.

Posted

Fact checked

Spero Therapeutics, Inc is a biotechnology business based in the US. Spero Therapeutics shares (SPRO) are listed on the NASDAQ and all prices are listed in US Dollars. Spero Therapeutics employs 57 staff and has a trailing 12-month revenue of around USD$11.1 million.

How to buy shares in Spero Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Spero Therapeutics. Find the stock by name or ticker symbol: SPRO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Spero Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Spero Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Spero Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Spero Therapeutics share price

Use our graph to track the performance of SPRO stocks over time.

Spero Therapeutics shares at a glance

Information last updated 2020-11-24.
52-week range USD$5.25 - USD$15.49
50-day moving average USD$13.7881
200-day moving average USD$12.5443
Wall St. target price USD$28.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.24

Buy Spero Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Spero Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Spero Therapeutics financials

Revenue TTM USD$11.1 million
Gross profit TTM USD$-47,628,000
Return on assets TTM -39.97%
Return on equity TTM -75%
Profit margin 0%
Book value $5.113
Market capitalisation USD$428.9 million

TTM: trailing 12 months

Shorting Spero Therapeutics shares

There are currently 1.9 million Spero Therapeutics shares held short by investors – that's known as Spero Therapeutics's "short interest". This figure is 3.7% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Spero Therapeutics shares can be evaluated.

Spero Therapeutics's "short interest ratio" (SIR)

Spero Therapeutics's "short interest ratio" (SIR) is the quantity of Spero Therapeutics shares currently shorted divided by the average quantity of Spero Therapeutics shares traded daily (recently around 259380.60941828). Spero Therapeutics's SIR currently stands at 7.22. In other words for every 100,000 Spero Therapeutics shares traded daily on the market, roughly 7220 shares are currently held short.

However Spero Therapeutics's short interest can also be evaluated against the total number of Spero Therapeutics shares, or, against the total number of tradable Spero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spero Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Spero Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0761% of the tradable shares (for every 100,000 tradable Spero Therapeutics shares, roughly 76 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Spero Therapeutics.

Find out more about how you can short Spero Therapeutics stock.

Spero Therapeutics share dividends

We're not expecting Spero Therapeutics to pay a dividend over the next 12 months.

Spero Therapeutics share price volatility

Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $5.25 up to $15.49. A popular way to gauge a stock's volatility is its "beta".

SPRO.US volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 1.56. This would suggest that Spero Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Spero Therapeutics overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site